Premium
Pharmacokinetics of pyropheophorbide‐a‐hexyl ether in the dog
Author(s) -
Payne John T.,
McCaw Dudley L.,
Casteel Stan W.,
Frazier Donita,
Rogers Kevin,
Tompson Robert V.
Publication year - 1996
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/(sici)1096-9101(1996)18:4<406::aid-lsm10>3.0.co;2-1
Subject(s) - pharmacokinetics , volume of distribution , photosensitizer , chemistry , pharmacology , ether , plasma clearance , distribution (mathematics) , drug , half life , toxicity , medicine , mathematical analysis , mathematics , organic chemistry
Background and Objectives Pyropheophorbide‐a‐hexyl ether (HPPH) is a new compound being investigated for use as a photosensitizer for photodynamic therapy; however, the pharmacokinetics are not known for any of the target species likely to be treated with this drug. The objective of this study was to determine the pharmacokinetic parameters of this drug prior to institution of a clinical trial in canine patients with various cancers. Study design, Materials and Methods. HPPH (0.3mg/kg I.V.) was administered to 12 dogs and blood samples were drawn at intervals for 24 hours and plasma HPPH concentrations were determined. Pharmacokinetic parameters were calculated for each dog. Results No evidence of toxicity was noted in any dog. The mean half‐life was calculated to be 26.98 ± 2.35 hrs. The mean clearance was 5.061 ± 0.214 ml/hr/kg. The mean volume of distribution of the central compartment was 0.069 ± 0.003 L/kg, and the mean steady state volume of distribution was 4.47 ± 0.25 L/kg. Conclusion. The conclusion is that 0.3 mg/kg HPPH injected intravenously resulted in measurable plasma levels for 24 hrs, and resulted in no detectable adverse reactions. © 1996 Wiley‐Liss, Inc.